--- title: "Primary Biliary Cholangitis CymaBay AFFIRM | Sutter Health" description: "AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis" url: "https://www.sutterhealth.org/research/clinical-trials/pbc-cymabay-cb8025-41837-affirm-1049142001" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Primary Biliary Cholangitis CymaBay AFFIRM # Primary Biliary Cholangitis (PBC) AFFIRM **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/pbc-cymabay-cb8025-41837-affirm-1049142001#enroll) #### Study details View study details on [www.clinicaltrials.gov](https://www.clinicaltrials.gov/study/NCT06051617). #### Locations - San Francisco #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis. ![Kidist K Yimam, M.D.](https://dyn.mktgcdn.com/p/3fH276sZ18zKXSL2IfJxLtpJhsit7g7DSeScWGy6fQc/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Kidist K Yimam, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/kidist-k-yimam-md-1049681096) ## Email us to enroll - [Email San Francisco](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Primary%20Biliary%20Cholangitis%20\(PBC\)%20AFFIRM%20in%20San%20Francisco&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Stress Urinary Incontinence PAS001 ProACT](https://www.sutterhealth.org/research/clinical-trials/stress-urinary-incontinence-pas001-proact-2080051902) Post Approval Study of the ProACT™ Adjustable Continence Therapy for Men **Status:** Open to Enrollment - Clinical trial ### [Chronic Nausea and Vomiting NAVIGATE](https://www.sutterhealth.org/research/clinical-trials/chronic-nausea-and-vomiting-navigate-2023207930) A Prospective Randomized Controlled Trial of Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System **Status:** Open to Enrollment - Clinical trial ### [Gastroparesis EXPEDITE](https://www.sutterhealth.org/research/clinical-trials/gastroparesis-expedite-2007479109) Examination of Programming with the Enterra® Therapy System (EXPEDITE) in a Double-Blinded, Randomized, Prospective Study in the Treatment of Nausea and Vomiting Symptoms Using Gastric Electrical Stimulation **Status:** Open to Enrollment - Clinical trial ### [Hepatitis LCAH3141 RE-AHFIRM](https://www.sutterhealth.org/research/clinical-trials/hepatitis-lcah3141-re-ahfirm-2075020771) RE-AHFIRM (RandomizEd Study of Larsucosterol in Alcohol-associated Hepatitis to Confirm saFety and effIcacy of tReatMent) **Status:** Open to Enrollment - Clinical trial ### [Kidney Transplant Patients EFC18554 FREXERA](https://www.sutterhealth.org/research/clinical-trials/kidney-transplant-patients-efc18554-frexera-2090973869) A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients **Status:** Coming Soon [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/pbc-cymabay-cb8025-41837-affirm-1049142001#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Primary Biliary Cholangitis CymaBay AFFIRM"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/pbc-cymabay-cb8025-41837-affirm-1049142001#medicalwebpage","name":"Primary Biliary Cholangitis (PBC) AFFIRM","description":"AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis","url":"https://www.sutterhealth.org/research/clinical-trials/pbc-cymabay-cb8025-41837-affirm-1049142001","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/pbc-cymabay-cb8025-41837-affirm-1049142001#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/pbc-cymabay-cb8025-41837-affirm-1049142001#breadcrumblist"},"mentions":[{"@type":"Person","name":"Kidist K Yimam, M.D.","url":"https://www.sutterhealth.org/research/investigators/kidist-k-yimam-md-1049681096","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/pbc-cymabay-cb8025-41837-affirm-1049142001#medicaltrial","name":"Primary Biliary Cholangitis (PBC) AFFIRM","alternateName":"AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis","url":"https://www.sutterhealth.org/research/clinical-trials/pbc-cymabay-cb8025-41837-affirm-1049142001","description":"To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.","identifier":"NCT06051617","code":{"@type":"MedicalCode","codeValue":"NCT06051617","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://www.clinicaltrials.gov/study/NCT06051617","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Liver Diseases and Transplant"},{"@type":"MedicalCondition","name":"Primary Biliary Cholangitis (PBC)"}],"studyLocation":[{"@type":"AdministrativeArea","name":"San Francisco"}]} ```